Calyxo, Inc. is a clinical-stage medical device company focused on developing and commercializing innovative solutions for kidney stone disease. The company's lead product, CVac, is designed to prevent the recurrence of kidney stones through a minimally invasive procedure that aims to alter the urinary environment to prevent stone formation.

Questa Capital is a venture growth equity firm focused on later-stage investing in the healthcare services, healthcare technology, and medical device sectors.

COM:QUESTACAPITAL

Calyxo, Inc.

Analysis Not Available